ArticleScientific reports2026
Preliminary phytochemical profiling and in vitro antibacterial activity of Lycium edgeworthii (Solanaceae) leaf extract against multidrug-resistant bacterial pathogens.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The escalating global crisis of antimicrobial resistance (AMR) necessitates the urgent discovery of novel therapeutic agents from underexplored plant sources. The genus Lycium (Solanaceae) is renowned for its rich phytochemistry, yet Lycium edgeworthii Dunal remains scientifically unexplored. This study presents the first comprehensive phytochemical profiling and antibacterial evaluation of L. edgeworthii leaf ethanolic extract against clinically relevant multidrug-resistant (MDR) bacterial pathogens. The extract was prepared via Soxhlet extraction (yield: 8.7% w/w) and subjected to qualitative phytochemical screening using standard protocols. Antibacterial activity was evaluated against Gram-positive (Staphylococcus aureus MTCC 96, Bacillus subtilis MTCC 121) and Gram-negative (Escherichia coli MTCC 443, Pseudomonas aeruginosa MTCC 424) bacteria using agar well diffusion and resazurin-based microdilution broth assays to determine zones of inhibition (ZOI) and minimum inhibitory concentrations (MICs). Phytochemical analysis confirmed the presence of alkaloids, flavonoids, terpenoids, saponins, coumarins, and glycosides. The extract exhibited significant, dose-dependent antibacterial activity. In the well diffusion assay, the largest inhibition zone was observed against P. aeruginosa (12.3 ± 0.6 mm at 100 mg/mL). However, MIC determination revealed greater efficacy against S. aureus (MIC = 0.39 mg/mL) and E. coli (MIC = 0.78 mg/mL), with higher MICs for P. aeruginosa and B. subtilis (1.56 mg/mL). This discrepancy between ZOI and MIC highlights the importance of employing complementary assays and suggests differential compound diffusion properties. The ethanolic leaf extract of L. edgeworthii possesses a diverse phytochemical profile and demonstrates significant, broad-spectrum antibacterial activity in vitro. Its notable efficacy against MDR pathogens, particularly S. aureus and E. coli, validates its ethnobotanical potential and positions it as a promising candidate for bioassay-guided isolation of novel antimicrobial leads. Future studies should focus on compound characterization, mechanistic investigations, and cytotoxicity evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.